Nogueira, F. S.Moreira, MABBorja-Cabrera, G. P.Santos, F. N.Menz, IParra, L. E.Xu, Z.Chu, H. J.Palatnik-de-Sousa, C. B.Luvizotto, MCR2014-02-262014-05-202014-02-262014-05-202005-09-23Vaccine. Oxford: Elsevier B.V., v. 23, n. 40, p. 4805-4810, 2005.0264-410Xhttp://hdl.handle.net/11449/15622Leishmune (R) vaccine is the first licensed vaccine against canine visceral leishmaniasis. It contains the Fucose-Mannose-ligand (FML) antigen of Leishmania donovani. The potential Leishmune (R) vaccine effect on the interruption of the transmission of the disease, was assayed by monitoring, in untreated (n = 40) and vaccinated dogs (n = 32) of a Brazilian epidemic area: the kala-azar clinical signs, the FML-seropositivity and the Leishmania parasite evidence by immunohistochemistry of skin and PCR for Leishmanial DNA of lymph node and blood samples. on month I I after vaccination, untreated controls showed: 25% of symptomatic cases, 50% of FML-seropositivity, 56.7% of lymph node PCR, 15.7% of blood PCR and 25% of immunohistochemical positive reactions. The Leishmune (R)-vaccinated dogs showed 100% of seropositivity to FML and a complete absence of clinical signs and of parasites (0%) in skin, lymph node and blood PCR samples (P < 0.01). The positivity in FML-ELISA in untreated dogs significantly correlates with the PCR in lymph node samples (p < 0.001) and with the increase in number of symptoms (p = 0.006) being strong markers of infectiousness. The absence of symptoms and of evidence of Leishmania DNA and parasites in Leishmune (R)-vaccinated animals indicates the non-infectious condition of the Leishmune (R)-vaccinated dogs. (c) 2005 Elsevier Ltd. All rights reserved.4805-4810engcanine visceral leishmaniasisFML-vaccinetransmission blocking vaccinesArtigo10.1016/j.vaccine.2005.05.011WOS:000232218600001Acesso restrito